Ney Carter Borges: Does APOC3 Inhibition Translates into Structural Coronary Plaque Modification
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“APOC3 Inhibition with Olezarsen and Coronary Atherosclerosis
The Essence – TIMI 73b imaging substudy evaluated whether intensive triglyceride-rich lipoprotein reduction with olezarsen translates into structural coronary plaque modification.
In this randomized, placebo – controlled trial, 468 patients with moderate hypertriglyceridemia and established or high cardiovascular risk underwent serial coronary CT angiography over 12 months.
Olezarsen produced profound lipid changes, including a 63.9% reduction in triglycerides, 71.9% reduction in remnant cholesterol, and a 16% decrease in apolipoprotein B (apoB), without affecting LDL cholesterol.
Despite these robust metabolic effects, the primary endpoint – percent change in noncalcified plaque volume (NCPV) – was not significantly different compared with placebo (Δ +2.98%; 95% CI −3.4 to 9.3; p equals 0.36).
Similarly, no meaningful differences were observed across secondary plaque components, including low-attenuation and total plaque volumes.
These findings highlight a critical mechanistic insight:
Substantial triglyceride and remnant cholesterol reduction alone may be insufficient to induce measurable short – term plaque regression, particularly when apoB lowering is modest.
Given that apoB reflects the total burden of atherogenic particles, the results reinforce its central role in atherosclerosis progression.
Longer – term outcome trials are required to determine whether APOC3 inhibition confers clinical cardiovascular benefit despite neutral imaging findings.”
More posts featuring Ney Carter Borges on Hemostasis Today.
-
May 28, 2026, 16:19James Farrell: The Power of Linked Electronic Health Records for Understanding Real Patient Journeys
-
May 28, 2026, 16:19Michael Makris: I Hope The Bleeding Disorders Community Supports Kedrion Initiative for FV Deficiency
-
May 28, 2026, 16:16Kamalben Prajapati at Vascular Discovery Conference 2026
-
May 28, 2026, 16:11Laura Dormer: Real-World Safety of DOACs vs LMWH in Cancer-Associated VTE Acroos Europe
-
May 28, 2026, 16:08Esau Martinez Ruiz: Proud to be Part of the Faculty at BDFLOW Summit26 in Brussels
-
May 28, 2026, 16:06Francisco Chacon-Lozsan: Why Anticoagulation in the ICU is not One Protocol?
-
May 28, 2026, 16:04When was the Last Time You Had Your Cholesterol Checked? – UNC Health
-
May 28, 2026, 16:03Paul Bolaji: ACTIVATE Study in Ghana Demonstrates Over 400% Increase in Stroke Thrombolysis
-
May 28, 2026, 15:57Lysanne van der Wal – Smit: Improving Care for Women Affected by HG at ICHG 2026